Rafał D.
- Country
- Poland
- Department
- AmiCare sp. z o.o. sp. k.
Research Overview
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis
- A Phase 1 Study of Afimkibart Effects on Cytochrome P450-Mediated Drug Metabolism in Patients With Active Ulcerative Colitis
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
Data & Insights
Has run more than one trial at 388 of 685 partner sites.
Specializations
Inflammatory Bowel Disease Management
Focused on treating Ulcerative Colitis and Crohn's Disease, exploring innovative therapeutic approaches for moderate to severe cases.
- Novel oral treatments
- Biologic therapies
- Long-term disease management
Specializes in evaluating therapeutic responses and achieving clinical remission in treatment-resistant cases.
Gastrointestinal Therapeutics
Investigates treatments for gastroparesis and specialized interventions for patients with ileostomy, focusing on improving digestive function and quality of life.
- Gastric motility disorders
- Post-surgical care
- Digestive system disorders
Explores innovative approaches to managing complex gastrointestinal conditions and their complications.
Clinical Innovation
Advances research in bowel urgency management and endoscopic improvement through combination therapy approaches and novel treatment modalities.
- Treatment optimization
- Therapeutic monitoring
- Clinical efficacy assessment
Evaluates cutting-edge therapeutic options for inflammatory bowel conditions resistant to conventional treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.